Publicidad
Caso clínico 02 de abril de 2015

Gammagrafía con 99mTc-sestamibi en hiperparatiroidismo con diagnóstico histológico de carcinoma de paratiroides

Referenciar Imprimir Descargar PDF

Referencias

  1. De Quervain VF. Parastruma maligna aberranta. Deut Zschr Chir 1909;100:334-52.
  2. Armstrong HG. Primary carcinoma of the parathyroid with report of a case. Bull Acad M Toronto 1938;11:105-10.
  3. Herrera AA, Aranda P, Díaz JA. Cáncer de paratiroides: revisión de literatura. REEMO 2007; 16:124-9.
  4. Sillero Sánchez A, Atienza Iglesias MA. Manejo diagnóstico-terapéutico del carcinoma de paratiroides. An Med Interna 2002;19:644-8.
  5. Cheon M, Choi JY, Lee JY, et al. Differential findings of Tc-99m dual-phase parathyroid scintigraphy between bening and malignant parathyroid. lesions in patients with primary hyperparathyroidism. Nucl Med Mol Imaging 2011;45:276-84.
  6. Arbad AS, Koizumi K, Toyama K, Araki T. Uptake of technetium-99m-tetrofosmin,technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med 1996;37:1551-6.
  7. Schantz A, Castelman B. Parathyroid carcinoma. A study of 70 cases. Cancer 1973;31:600-5.
  8. Bondeson L, Sandelin K, Grimelius L. Histological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol 1993;17:820-9.
  9. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in U.S. between 1985-1995: a national cancer data base report. Cancer 1999;86:538-44.
  10. Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistant and recurrent parathyroid carcinoma. Arch Surg 2001;136:878-85.